AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01646177
Drug: 50 mg etanercept
RxNorm normalized name: etanercept 50 MG/ML
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered SC
Trial: NCT01646177
Drug: 80 mg ixekizumab
RxNorm normalized name: ixekizumab 80 MG/ML
DrugBank: Ixekizumab (DB11569)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered SC
Trial: NCT03536507
Drug: ACETAZOLAMIDE oral capsule
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
Trial: NCT03990077
Drug: HL-085
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HL-085 ( Capsule) is one MEK inhibitor.
Trial: NCT03990077
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel is an antineoplastic drug by inhibiting microtubule depolymerization, and attenuating of the effects of bcl-2 and bcl-xL gene expression.
Trial: NCT03432442
Drug: Ivermectin
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ivermectin once every 24 hours for three administrations
Trial: NCT00668265
Drug: Quetiapine
RxNorm normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosage is 50 - 300 mg, once daily, at bedtime.
Trial: NCT01613482
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly, 2mg/kg of corporal weight
Trial: NCT01613482
Drug: Other chemotherapy in association with Trastuzumab
RxNorm normalized name: antibiotics in combination with other drugs
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: other chemotherapy is possible to associate with Trastuzumab as well as a change of chemotherapy protocol is possible while maintening Trastuzumab 8 weeks is required between last injection of chemotherapy and first radiotherapy session
Trial: NCT04596839
Drug: Remdesivir
RxNorm normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remdesivir INN 100 mg lyophilized powder for infusion
Trial: NCT00519246
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline 5 ml administrated intravenously
Trial: NCT01699113
Drug: YF476
RxNorm normalized name: Fexofenadine
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will be randomised to once daily treatment by mouth for 6 weeks with:~* YF476 100 mg; or~* rabeprazole 20 mg; or~* a combination of YF476 100 mg and rabeprazole 20 mg.
Trial: NCT01699113
Drug: Rabeprazole
RxNorm normalized name: Rabeprazole
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will be randomised to once daily treatment by mouth for 6 weeks with:~* YF476 100 mg; or~* rabeprazole 20 mg; or~* a combination of YF476 100 mg and rabeprazole 20 mg.
Trial: NCT00056277
Drug: lamotrigine
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05538026
Drug: Mesalazine
RxNorm normalized name: mesalazine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: daily dose of 3 g (2 g orally + 1 g rectally)
Trial: NCT00519246
Drug: NSAID
RxNorm normalized name: Ansaid
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flurbiprofen Axetil 50 mg i.v.
Trial: NCT00519246
Drug: NSAID
RxNorm normalized name: Ansaid
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flurbiprofen Axetil 100 mg i.v.
Trial: NCT00476164
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2 doses of 1g 14 days apart
Trial: NCT02351440
Drug: duloxetine
RxNorm normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients will be randomized to receive either duloxetine or placebo
Trial: NCT00440180
Drug: Anastrozole
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 mg qd for 4 months
Trial: NCT00030433
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00030433
Drug: irinotecan hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01985425
Drug: Colchicine 0.6 mg
RxNorm normalized name: colchicine 0.6 MG
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01985425
Drug: Placebo Colchicine
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01562847
Drug: Nilotinib
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be treated with 800 mg nilotinib daily.
Trial: NCT01274325
Drug: Seretide
RxNorm normalized name: seractide
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will take Seretide (25/125) 2 puffs twice a day for 4 weeks
Trial: NCT03069820
Drug: docetaxel and cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients receive TP (docetaxel and cisplatin) chemotherapy
Trial: NCT00968071
Drug: Decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg/m\^2 IV over an hour and half daily for 5 days.
Trial: NCT00968071
Drug: Gemtuzumab Ozogamicin
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 3 mg/m\^2 IV on day 5.
Trial: NCT01516619
Drug: Romiplostim
RxNorm normalized name: Romiplostim
DrugBank: Romiplostim (DB05332)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Romiplostim will be administered subcutaneously at a dose of 250 μg on the 1st, 3rd and 5th days after the last day of chemotherapy delivery and, then, every two days until the achievement of 75.000 plt/μL.~In the case of unsuccessful use of romiplostim after the second chemotherapy course, dose escalation to 500 μg/day, with the same above-mentioned schedule, will be indicated after the third course and for all the further courses, with a maximum of 8.
Trial: NCT00484484
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketamine
Trial: NCT00211224
Drug: Riluzole
RxNorm normalized name: Riluzole
DrugBank: Riluzole (DB00740)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04521751
Drug: EMP16-02 120 mg orlistat/40 mg acarbose
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMP16-02 capsules are composed of three pharmaceutical fractions (granules denoted G1, G2 and G3). G1= Prolonged release of acarbose, G2= Enteric-coated granule fraction containing orlistat and acarbose, G3= Orlistat with a delayed on-set release mechanism.
Trial: NCT04521751
Drug: EMP16-02 150 mg orlistat/50 mg acarbose
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMP16-02 capsules are composed of three pharmaceutical fractions (granules denoted G1, G2 and G3). G1= Prolonged release of acarbose, G2= Enteric-coated granule fraction containing orlistat and acarbose, G3= Orlistat with a delayed on-set release mechanism.
Trial: NCT04398823
Drug: Sclerosing foam of Lauromacrogol
RxNorm normalized name: lauromacrogols
DrugBank: Rosin (DB11165)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in FS will receive enteroscopy with the sclerosing foam of lauromacrogol.
Trial: NCT02985840
Drug: Ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients receive intravenous ondansetron (4mg) followed by two 5ml normal saline flushes
Trial: NCT02985840
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients receive intravenous ondansetron(4mg) followed by intravenous dexamethasone (4mg), followed by a single 5ml normal saline flush
Trial: NCT00144495
Drug: recombinant human erythropoietin
RxNorm normalized name: RECOMBINANT HUMAN ERYTHROPOIETIN ALFA
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3600IU(s.c.)/week for 7 weeks and 54000IU(s.c.)/week for 5 weeks
Trial: NCT00144495
Drug: recombinant human erythropoietin
RxNorm normalized name: RECOMBINANT HUMAN ERYTHROPOIETIN ALFA
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 36000IU(s.c.)/week for 12 weeks
Trial: NCT01448707
Drug: Darunavir
RxNorm normalized name: Darunavir
DrugBank: Darunavir (DB01264)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Darunavir (DRV): type = exact number, unit = mg, number = 800, form = tablet, route = oral use
Trial: NCT01448707
Drug: Ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ritonavir (rtv): type = exact number, unit = mg, number = 100, form = tablet, route = oral use
Trial: NCT04145700
Drug: Ramucirumab
RxNorm normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ramucirumab given IV
Trial: NCT04145700
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine given IV
Trial: NCT04145700
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel given IV
Trial: NCT01259089
Drug: erlotinib hydrochloride
RxNorm normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT01259089
Drug: Hsp90 inhibitor AUY922
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: AUY922 (DB11881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02229851
Drug: somapacitan
RxNorm normalized name: Somapacitan
DrugBank: Somapacitan (DB15093)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered subcutaneously (s.c., under the skin) once weekly for 26 weeks following 8 weeks of titration. Extension of 44 weeks' treatment following 8 weeks of titration.
Trial: NCT00655811
Drug: Capsaicin
RxNorm normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical application, 0.1%, Capzasin HP; Chattem Inc., Chattanooga, TN, U.S.A
Trial: NCT02229851
Drug: somatropin
RxNorm normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously (s.c., under the skin) once daily for 26 weeks following 8 weeks of titration. Re-randomisation to extension of 44 weeks' treatment following 8 weeks of titration.
Trial: NCT02297100
Drug: Onabotulinumtoxin A
RxNorm normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: 100 units of botox spread out among 10 separate injections
Trial: NCT00744237
Drug: Nebivolol
RxNorm normalized name: Nebivolol
DrugBank: Nebivolol (DB04861)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Nebivolol 5 mg (overencapsulated 5-mg marketed tablet), oral administration~* Nebivolol 10 mg (overencapsulated 10-mg marketed tablet), oral administration~* Nebivolol 20 mg (overencapsulated 20-mg marketed tablet) oral administration~* Nebivolol 40 mg (two overencapsulated 20-mg tablets) oral administration
Trial: NCT00744237
Drug: Metoprolol ER
RxNorm normalized name: Hydrochlorothiazide-Metoprolol ER
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Metoprolol ER 50 mg (overencapsulated 50-mg tablet) oral administration~* Metoprolol ER 100 mg (two overencapsulated 50-mg tablets) oral administration~* Metoprolol ER 200 mg (overencapsulated 200-mg tablet) oral administration~* Metoprolol ER 400 mg (two overencapsulated 200-mg tablets) oral administration
Trial: NCT00744237
Drug: HCTZ
RxNorm normalized name: HCTZ
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * HCTZ 12.5 mg (overencapsulated 12.5 capsule), oral administration~* HCTZ 25 mg (two capsules, overencapsulated 12.5-mg capsules), oral administration
Trial: NCT00000206
Drug: Buprenorphine
RxNorm normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04215445
Drug: Empagliflozin 25 MG
RxNorm normalized name: empagliflozin 25 MG
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tab.empagliflozin 25mg once daily for 28 days
Trial: NCT01913834
Drug: Forsteo
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous administration 20 micrograms
Trial: NCT01913834
Drug: CP046 PTH CriticalSorb
RxNorm normalized name: PTH
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparison of different doses of drug and nasal delivery devices
Trial: NCT02429453
Drug: Four Factor Prothrombin Complex Concentrate
RxNorm normalized name: Prothrombin complex concentrate
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A purified, non-activated prothrombin complex concentrate containing factors II, VII, IX and X and proteins C \& S
Trial: NCT00541177
Drug: atropine
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25% atropine
Trial: NCT00541177
Drug: tropicamide
RxNorm normalized name: Tropicamide
DrugBank: Tropicamide (DB00809)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5% tropicamide
Trial: NCT00743431
Drug: Caelyx (Pegylated Lyposomal Doxorubicin)
RxNorm normalized name: Caelyx
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pegylated Lyposomal Doxorubicin, 50 mg/m2 every 4 weeks for 6 cycles.
Trial: NCT00771693
Drug: Insulin aspart (Novorapid®)
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: a cross-over study with subcutaneous injection of insulin aspart 0.1U/kg, 0.2u/kg or placebo, before the meal, on 3 different occasions.
Trial: NCT03780595
Drug: Passiflora incarnata
RxNorm normalized name: Passiflora incarnata
DrugBank: Passiflora incarnata flower (DB13974)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Passiflora pills administration up to 6 pills per day
Trial: NCT01506973
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01506973
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01506973
Drug: Abraxane
RxNorm normalized name: Abraxane
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00613743
Drug: mouth wash with morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: morphine solution 0.2% concentration; 15ml per unit mouthwash 6 time à day
Trial: NCT03780595
Drug: Control
RxNorm normalized name: Control
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control pills administration up to 6 pills per day
Trial: NCT03211117
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03460808
Drug: atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin was used in combination with acetylcysteine and danazol.
Trial: NCT03460808
Drug: Acetylcysteine
RxNorm normalized name: Acetylcysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylcysteine was used in combination with atorvastatin and danazol.
Trial: NCT03460808
Drug: Danazol
RxNorm normalized name: Danazol
DrugBank: Danazol (DB01406)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Danazol was used in combination with atorvastatin and acetylcysteine or as the monotherapy
Trial: NCT01840410
Drug: Ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab 0.5mg/0.5mL was administered intravitreally to the participant.
Trial: NCT03652441
Drug: Brentuximab Vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: BV will be administered i.v. at 1.8mg/kg at 3-weekly intervals for up to 16 infusions
Trial: NCT02130323
Drug: Imiquimod
RxNorm normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 12.5mg (5%) once a week vaginally for 16 weeks
Trial: NCT03617900
Drug: Ginger
RxNorm normalized name: Ginger
DrugBank: Ginger (DB10344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger extract is contains 100 mg/capsules. Use 2 capsules 3 times/day
Trial: NCT03617900
Drug: Paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg paracetamol. use in need
Trial: NCT01004250
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500 milligram per square meter (mg/m²) given intravenously on Day 1 of each 21-day cycle for four cycles of Induction Therapy, and continued in Maintenance Therapy until progression or unacceptable toxicity.
Trial: NCT01004250
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/m² given intravenously on Day 1 of 21-day cycle for a maximum of 4 cycles
Trial: NCT01004250
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 7.5 milligram per kilogram (mg/kg) given intravenously on Day 1 of 21-day cycle for four cycles of Induction Therapy, and continued in Maintenance Therapy until progression or unacceptable toxicity
Trial: NCT02653014
Drug: KBP-5074
RxNorm normalized name: KBP-COVID-19
DrugBank: KBP-COVID-19 (DB15858)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00034788
Drug: Becaplermin
RxNorm normalized name: Becaplermin
DrugBank: Becaplermin (DB00102)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00831662
Drug: Diquafosol tetrasodium ophthalmic solution, 2%
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One to two drops in each eye QID for 6 weeks
Trial: NCT00318539
Drug: Quetiapine
RxNorm normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01854294
Drug: GM604
RxNorm normalized name: GM604
DrugBank: Alirinetide (DB17007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM604 treated group subject will receive a slow IV bolus injection (\~1min) of 6.4 mL (320mg @50 mg/mL=6.4 mL) for each dose. A total of 6 doses will be administered over two weeks (on Mondays, Wednesdays and Fridays for the first 2 weeks).
Trial: NCT01675453
Drug: 7.2% NaCl plus 6% hydroxyethyl starch 200/0.5
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03472287
Drug: Diacerein 1% Ointment
DrugBank: Diacerein (DB11994)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diacerein 1% Ointment administered topically
Trial: NCT01504477
Drug: Panitumumab and bortezomib
RxNorm normalized name: Panitumumab
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Panitumumab 6 mg/kg IV over 60 minutes on Day -14 (first cycle only), then Day 1 and 15 of each 28-day cycle.~Bortezomib will be administered in escalating doses until the maximum tolerated dose is determined and then at the maximum tolerated dose as an IV bolus injection over 3-5 seconds on Day 1, 8, and 15 of each 28-day cycle.
Trial: NCT00605319
Drug: Toviaz (Fesoterodine)
RxNorm normalized name: Toviaz
DrugBank: Fesoterodine (DB06702)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4mg to 8mg by mouth once daily
Trial: NCT02342314
Drug: LY3143753 (Part A)
RxNorm normalized name: Echinacea, aerial parts
DrugBank: Echinacea (DB14240)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered via SC injection
Trial: NCT02342314
Drug: LY3185643 (Part B)
RxNorm normalized name: SODIUM CHLORITE 0.0256 kg in 1 kg TOPICAL SPRAY [Chlorsan 105 Part B]
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered via SC injection
Trial: NCT03863015
Drug: Tocilizumab 20 Mg/mL Intravenous Solution
RxNorm normalized name: tocilizumab 20 mg/mL intravenous solution
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab is suspended in isotonic saline to a total volume of 100mL prior to infusion
Trial: NCT02342314
Drug: rGlucagon (Part B)
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered via SC injection
Trial: NCT03312413
Drug: Dexmedetomidine Hydrochloride
RxNorm normalized name: Dexmedetomidine Hydrochloride
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine Hydrochloride 0.2 μg·kg-1·h-will be administered to participants by intravenous infusion from incision to 20-30 minutes before the end of surgery
Trial: NCT03312413
Drug: Dexmedetomidine Hydrochloride
RxNorm normalized name: Dexmedetomidine Hydrochloride
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine Hydrochloride 0.5 μg·kg-1·h-1 will be administered to participants by intravenous infusion from incision to 20-30 minutes before the end of surgery